Article Details

Arbutus Biopharma (NASDAQ:ABUS) Rating Lowered to Sell at Zacks Investment Research

Retrieved on: 2021-01-18 21:43:11

Tags for this article:

Click the tags to see associated articles and topics

Arbutus Biopharma (NASDAQ:ABUS) Rating Lowered to Sell at Zacks Investment Research. View article details on HISWAI: https://www.marketbeat.com/instant-alerts/nasdaq-abus-a-buy-or-sell-right-now-2021-01/

Excerpt

According to Zacks, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up